COMPARISON
Corticorelin vs Oxytocin
3 attributes held for at least one of the two. 2 differ. Each value carries the register it came from and the date that register was read.
Answer
Corticorelin is authorised or registered in 0 and Oxytocin in 9 of the 10 registers read. Corticorelin: No trial states a phase. Oxytocin: highest phase Phase 4 (after approval). 1 registered trial includes both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Corticorelin | Oxytocin | |
|---|---|---|
| Registered trials differs | 39 clinicaltrials.gov · 2026-10-03 | 952 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | Not checked no record of "fdaLabel" for corticorelin | FDA label, application not recorded: GUNA-GERIATRICS openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Nothing on record ema read 2026-08-31 | Nothing on record ema read 2026-08-31 |
LEGAL STATUS
Approval in each country read
| Country | Corticorelin | Oxytocin | Register |
|---|---|---|---|
| United States | Not on the register | FDA-approved | Regulator FDA |
| European Union | Not on the register | Not on the register | Regulator EMA |
| United Kingdom | Not on the register | Authorised | Regulator MHRA |
| Canada | Not on the register | Authorised | Regulator Health Canada |
| Australia | Status unknown | Registered | TGA |
| Switzerland | Not on the register | Authorised | Regulator Swissmedic |
| Brazil | Not on the register | Registado | Regulator ANVISA |
| Serbia | Not on the register | Authorised | Regulator ALIMS |
| Singapore | Not on the register | Registered | Regulator HSA |
| Turkey | Not on the register | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
1 registered trial includes both
| NCT04902235 | Identification and Clinical Relevance of an Oxytocin Deficient State (CRH Study) COMPLETED · updated 2024-04-03 |
|---|
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.